IP Library Granted Patent US 9,603,828
Granted Patent B2
US 9,603,828 · App. 14/404,781 · Granted Mar 28, 2017

Sulforaphane isolation and purification

Inventors: Sahadeva Reddy Damireddi (Brevard, NC); Kpakpo Ambroise Akue (Asheville, NC); Jared K. Nelson (Pisgah Forest, NC); Albert Roger Frisbee (Hendersonville, NC); Peter Wyatt Newsome (Horseshoe, NC)
Assignee: PharmAgra Labs, Inc.
A61K31/275A61K47/4823A61K47/48969B82Y5/00C07C331/20C08B37/0015C08L5/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,603,828
App. No.
14/404,781
Granted
Mar 28, 2017
Kind
B2
Abstract

The present invention relates to methods of isolating and purifying sulforaphane. More specifically, the present invention relates to methods of isolating and purifying sulforaphane from natural sources. The present invention also relates to methods of forming high purity complexes of sulforaphane with cyclodextrin.

Claims (16)

1. A method of isolating sulforaphane and/or a sulforaphane analog from a natural source thereof, the method comprising:

a) mixing the natural source of sulforaphane and/or sulforaphane analog, or an extract prepared from the natural source, wherein the purity of the sulforaphane and/or the sulforaphane analog in the extract is less than 75%, with cyclodextrin in a suitable solvent and with or without heat;

b) cooling the mixture to a temperature within the range of −10° C. to +25° C. to promote the formation of a precipitate of a complex between the sulforaphane or sulforaphane analog and the cyclodextrin; and

c) collecting the precipitate formed.

2. A method according to claim 1 , wherein the cyclodextrin is selected from the group consisting of W6 (alpha) cyclodextrin, W7 (beta) cyclodextrin, W8 (gamma) cyclodextrin, derivatives thereof, and mixtures thereof.

3. A method according to claim 1 , wherein the cyclodextrin is W6 (alpha) cyclodextrin.

4. A method according to claim 1 , wherein the analog of sulforaphane is selected from the group consisting of sulforaphene, Erucin, Erysolin, and mixtures thereof.

5. A method according to claim 1 , wherein the method further comprises:

dissolving the cyclodextrin in a solvent prior to mixing with the sulforaphane or an analog thereof.

6. A method according to claim 5 , wherein the solvent is water.

7. A method according to claim 1 , wherein the mixture is cooled to a temperature of between about −10° C. to about 15° C.

8. A method according to claim 1 , wherein the mixture is cooled to a temperature of between about −5° C. to about 5° C.

9. A method according to claim 1 , wherein the method further comprises recrystallizing the precipitate and filtering the resulting solid from the recrystallization.

10. A method according to claim 9 , wherein the recrystallization is accomplished by dissolving the precipitate in a solvent and cooling the mixture of the precipitate and the solvent to below room temperature and filtering the resulting solid.

11. A method according to claim 1 , wherein the purity of the sulforaphane and/or a sulforaphane analog in the extract prepared from the natural source is less than about 63%.

12. A method according to claim 1 , wherein the purity of the sulforaphane and/or a sulforaphane analog in the extract prepared from the natural source is less than about 24%.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2015
From: DAMIREDDI, SAHADEVA REDDY; AKUE, KPAKPO AMBROISE; NELSON, JARED K.; FRISBEE, ALBERT ROGER; NEWSOME, PETER WYATT
To: PHARMAGRA LABS, INC.
Reel/Frame 036247/0962 →
Continuity (2)
Provisional Application 61654300 · Jun 1, 2012
Related Publication 20150119359A1 · Apr 30, 2015